Advertisement

GATA1 promotes colorectal cancer cell proliferation, migration and invasion via activating AKT signaling pathway

  • Junhui Yu
  • Ming Liu
  • Hui Liu
  • Lei ZhouEmail author
Article

Abstract

GATA1, a member of the GATA transcription factor family, was reported to play a role in development and progression of erythroid cells and breast cancer cells. However, the role of GATA1 in colorectal cancer (CRC) is unknown. Here, we demonstrate that GATA1 was upregulated in CRC tissues compared with normal tissues, and predicted poor clinical outcome in CRC. Biological functional analyses showed that GATA1 knockdown decreased CRC cells proliferation, migration and invasion, and regulated the process of epithelial–mesenchymal transition (EMT). Moreover, silencing of GATA1 suppressed colorectal tumor growth in nude mice. Mechanistically, GATA1 overexpression significantly increased the activity of PI3K/AKT signaling pathway in CRC cells. These data provide insight into the important role of GATA1 in CRC progression and suggest that GATA1 is a potential therapeutic target for CRC.

Keywords

Colorectal cancer GATA1 Tumor progression AKT 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All applicable international, national, and institutional guidelines for the care and use of animals were followed.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Siegel RL, Miller KD, Jernal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30CrossRefGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A (2017) Colorectal cancer statistics, 2017. CA Cancer J Clin 67:177–193CrossRefGoogle Scholar
  3. 3.
    Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Ballegooijen MV, Zauber AG, Jemal A (2012) Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev 21:728–736CrossRefGoogle Scholar
  4. 4.
    Imperiale TF, Juluri R, Sherer EA, Glowinski EA, Johnson CS, Morelli MS (2014) A risk index for advanced neoplasia on the second surveillance colonoscopy in patients with previous adenomatous polyps. Gastrointest Endosc 80:471–478CrossRefGoogle Scholar
  5. 5.
    Laukoetter MG, Mennigen R, Hannig CM, Osada N, Rijcken E, Vowinkel T, Krieglstein CF, Senninger N, Anthoni C, Bruewer M (2011) Intestinal cancer risk in Crohn’s disease: a meta-analysis. J Gastrointest Surg 15:576–583CrossRefGoogle Scholar
  6. 6.
    Cunningham D, Atkin W, Lenz H-J, Lynch HT, Minsky B, Nordlinger B, Starling N (2010) Colorectal cancer. Lancet 375:1030–1047CrossRefGoogle Scholar
  7. 7.
    Bockelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B (2015) Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol 54:5–16CrossRefGoogle Scholar
  8. 8.
    Boland PM, Ma WW (2017) Immunotherapy for colorectal cancer. Cancers (Basel) 9:50CrossRefGoogle Scholar
  9. 9.
    Syn NL, Teng MWL, Mok TSK, Soo RA (2017) De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 18:e731–e741CrossRefGoogle Scholar
  10. 10.
    Zheng R, Blobel GA (2010) GATA transcription factors and cancer. Genes Cancer 1:1178–1188CrossRefGoogle Scholar
  11. 11.
    Shimizu R, Engel JD, Yamamoto M (2008) GATA1-related leukaemias. Nat Rev Cancer 8:279–287CrossRefGoogle Scholar
  12. 12.
    Boidot R, Vegran F, Jacob D, Chevrier S, Cadouot M, Feron O, Solary E, Lizard-Nacol S (2010) The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. Oncogene 29:2577–2584CrossRefGoogle Scholar
  13. 13.
    Zhang Y, Liu J, Lin J, Zhou L, Song Y, Wei B, Luo X, Chen Z, Chen Y, Xiong J, Xu X, Ding L, Ye Q (2016) The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer. Oncotarget 7:9859–9875Google Scholar
  14. 14.
    Li Y, Ke Q, Shao Y, Zhu G, Li Y, Geng N, Jin F, Li F (2015) GATA1 induces epithelial-mesenchymal transition in breast cancer cells through PAK5 oncogenic signaling. Oncotarget 6:4345–4356Google Scholar
  15. 15.
    Feng Y, Xu X, Zhang Y, Ding J, Wang Y, Zhang X, Wu Z, Kang L, Liang Y, Zhou L, Song S, Zhao K, Ye Q (2015) HPIP is upregulated in colorectal cancer and regulates colorectal cancer cell proliferation, apoptosis and invasion. Sci Rep 5:9429CrossRefGoogle Scholar
  16. 16.
    evans T, Reitman M, Felsenfeld G (1988) An erythrocyte-specific DNA-binding factor recognizes a regulatory sequence common to all chicken globin genes. Proc Natl Acad Sci USA 85:5976–5980CrossRefGoogle Scholar
  17. 17.
    Krepischi ACV, Maschietto M, Ferreira EN, Silva AG, Costa SS, Cunha IWD, Barros BDF, Grundy PE, Rosenberg C, Carraro DM (2016) Genomic imbalances pinpoint potential oncogenes and tumor suppressors in Wilms tumors. Mol Cytogenet 9:20CrossRefGoogle Scholar
  18. 18.
    Altom DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455–7464CrossRefGoogle Scholar
  19. 19.
    Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14:381–395CrossRefGoogle Scholar
  20. 20.
    Xue G, Hemmings BA (2013) PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst 105:393–404CrossRefGoogle Scholar
  21. 21.
    Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, Roy FV, Lee-Kwon W, Donowitz M, Tsichlis PN, Larue L (2003) The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 63:2172–2178Google Scholar
  22. 22.
    Lamouille S, Derynck R (2007) Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178:437–451CrossRefGoogle Scholar
  23. 23.
    Pon YL, Zhou HY, Cheung ANY, Ngan HYS, Wong AST (2008) p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res 68:6524–6532CrossRefGoogle Scholar
  24. 24.
    Smith AP, Verrecchia A, Faga G, Doni M, Perna D, Martinato F, Guccione E, Amati B (2009) A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene 28:422–430CrossRefGoogle Scholar
  25. 25.
    Scaltriti M, Baselga J (2006) The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12:5268–5272CrossRefGoogle Scholar
  26. 26.
    Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA (2015) Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta 1855:104–121Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Peritoneal Cancer Surgery, Beijing Shijitan HospitalCapital Medical UniversityBeijingPeople’s Republic of China
  2. 2.Department of SurgeryBeijing Zhanlanlu HospitalBeijingPeople’s Republic of China
  3. 3.Department of Oncology, Huguosi Hospital of Traditional Chinese MedicineBeijing University of Chinese MedicineBeijingPeople’s Republic of China
  4. 4.Department of Oncology, Beijing Shijitan HospitalCapital Medical UniversityBeijingPeople’s Republic of China

Personalised recommendations